Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bausch HealthBHC -2.03%58 Debt-to-Equity is -10.10 as of Mar. 2026. GuruFocus rates BHC with a GF Score™ of 58/100 and a GF Value™ of $7.93 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 813 Drug Manufacturers companies, Bausch Health ranks worse than 123001.11% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Bausch Health's Debt-to-Equity or its related term are showing as below:
BHC'
s Debt-to-Equity Range Over the Past 10 Years
Min: -213.72 Med: -13.5 Max: 51.39
Current: -10.1
During the past 13 years, the highest Debt-to-Equity Ratio of Bausch Health was 51.39. The lowest was -213.72. And the median was -13.50.
BHC's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.27
vs BHC: -10.10
Bausch Health (NYSE:BHC) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Bausch Health Debt-to-Equity Related Terms
Bausch Health Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Bausch Health's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch Health Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bausch Health's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Bausch Health's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch Health (BHC) has a Debt-to-Equity of -10.10 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bausch Health and its competitors. According to the industry distribution chart, Bausch Health ranks #999999 out of 813 companies in the Drug Manufacturers industry.
Is Bausch Health's Debt-to-Equity too high?
Bausch Health's current Debt-to-Equity is -10.10. Based on the distribution chart, Bausch Health ranks #999999 out of 813 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bausch Health has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bausch Health's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bausch Health ranks #999999 out of 813 companies for Debt-to-Equity. This places Bausch Health in the lower half of its industry. The industry median Debt-to-Equity is 0.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bausch Health and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch Health's current Debt-to-Equity is -10.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch Health stock overvalued right now?
Based on GuruFocus' analysis, Bausch Health (BHC) is currently considered Possible Value Trap. The stock's GF Value™ is $7.93, compared to a current price of $4.83 — trading 39.1% below its estimated fair value. The current Debt-to-Equity is -10.10. Bausch Health's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Bausch Health (BHC), the current Debt-to-Equity is -10.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch Health (BHC) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued.
The current stock price of $4.83 is trading 39.1% below its estimated GF Value™ of $7.93.
GuruFocus considers Bausch Health to be Possible Value Trap.
Key valuation signals for BHC:
Debt-to-Equity: -10.10
GF Value™: $7.93 vs. price of $4.83 (39.1% below fair value)
No single metric tells the full story. See the BHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
58GF Score
Get the complete analysis for BHC
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BHC has been successfully added to your 
